VALLEY FORGE, Pa.--(BUSINESS WIRE)--Oct. 29, 2012--
AmerisourceBergen Corporation (NYSE: ABC) today announced that Lawrence
C. Marsh, 52, will join the company in the new role of Chief Strategy
Officer and Senior Vice President, New Market Development, effective
November 12, 2012. Marsh will be responsible for enhancing the Company’s
long-term strategic plan, identifying new market opportunities, and
managing enterprise-wide risk.
“I am thrilled that Larry Marsh has decided to join AmerisourceBergen,”
said Steven H. Collis, President and Chief Executive Officer. “I have
respected his intellect and industry insights for many years, and I am
very pleased to welcome him as part of our leadership team. His
analytical expertise in both financial performance and market growth
opportunities will strengthen our efforts to expand our existing
businesses, both in the US and beyond, and to increase our breadth of
offerings and drive shareholder value with disciplined acquisitions.”
Most recently, Marsh was Managing Director, Equity Research at Barclays,
where he covered the healthcare distribution and technology industries
since 2008. Prior to joining Barclays, he held similar equity research
positions at Lehman Brothers, Salmon Smith Brothers, and Wheat First
Butcher Singer. Marsh has been a highly-ranked member of the annual Institutional
Investor All-America Research Team for the past 14 years.
Marsh has served on the board of trustees at his alma mater, The
University of Richmond, is currently trustee emeritus, and has served as
Chairman of its $3 billion endowment arm, Spider Management Corporation.
About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both healthcare providers and pharmaceutical manufacturers in
the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from niche
premium logistics and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With more than $80 billion in annual
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs approximately 13,000 people. AmerisourceBergen is ranked #29 on
the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
Forward-Looking Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. These statements are based on management's current expectations
and are subject to uncertainty and change in circumstances. Among the
factors that could cause actual results to differ materially from those
projected, anticipated or implied are the following: changes in
pharmaceutical market growth rates; the loss of one or more key customer
or supplier relationships; changes in customer mix; customer
delinquencies, defaults or insolvencies; supplier defaults or
insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract
or other dispute with customers or suppliers; federal and state
government enforcement initiatives to detect and prevent suspicious
orders of controlled substances and the diversion of controlled
substances; qui tam litigation for alleged violations of fraud
and abuse laws and regulations and/or any other laws and regulations
governing the marketing, sale, purchase, and/or dispensing of
pharmaceutical products or services and any related litigation,
including shareholder derivative lawsuits; changes in federal and state
legislation or regulatory action affecting pharmaceutical product
pricing or reimbursement policies, including under Medicaid and
Medicare; changes in regulatory or clinical medical guidelines and/or
labeling for the pharmaceutical products we distribute, including
certain anemia products; price inflation in branded pharmaceuticals and
price deflation in generics; greater or less than anticipated benefit
from launches of the generic versions of previously patented
pharmaceutical products; significant breakdown or interruption of our
information technology systems; our inability to continue to implement
an enterprise resource planning (ERP) system to handle business and
financial processes and transactions (including processes and
transactions relating to our customers and suppliers) of
AmerisourceBergen Drug Corporation operations as intended without
functional problems, unanticipated delays and/or cost overruns; success
of integration, restructuring or systems initiatives; interest rate and
foreign currency exchange rate fluctuations; risks associated with
international business operations, including non-compliance with the
U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic
sanctions and import laws and regulations; economic, business,
competitive and/or regulatory developments outside of the United States;
changes and/or potential changes in Canadian provincial legislation
affecting pharmaceutical product pricing or service fees or regulatory
action by provincial authorities in Canada to lower pharmaceutical
product pricing and service fees; the impact of divestitures or the
acquisition of businesses that do not perform as we expect or that are
difficult for us to integrate or control; our inability to successfully
complete any other transaction that we may wish to pursue from time to
time; changes in tax laws or legislative initiatives that could
adversely affect our tax positions and/or our tax liabilities or adverse
resolution of challenges to our tax positions; increased costs of
maintaining, or reductions in our ability to maintain, adequate
liquidity and financing sources; volatility and deterioration of the
capital and credit markets; and other economic, business, competitive,
legal, tax, regulatory and/or operational factors affecting our business
generally. Certain additional factors that management believes could
cause actual outcomes and results to differ materially from those
described in forward-looking statements are set forth (i) in Item 1A
(Risk Factors) in the Company's Annual Report on Form 10-K for the
fiscal year ended September 30, 2011 and elsewhere in that report and
(ii) in other reports filed by the Company pursuant to the Securities
Exchange Act of 1934.
Source: AmerisourceBergen Corporation
AmerisourceBergen Corporation
Barbara Brungess,
610-727-7199
bbrungess@amerisourcebergen.com